Bowel perforation in steroid-treated patients

Area of Science:

• Gastroenterology
• Surgical Outcomes
• Pharmacology

Background:

• Glucocorticosteroid (GCS) therapy is associated with high mortality rates in patients experiencing gastrointestinal perforation.
• Understanding the impact of GCS dosage on clinical presentation and outcomes is crucial for timely intervention.

Observation:

• A study of 79 patients identified three groups based on GCS dosage: perioperative coverage, low-dose (<20 mg prednisone daily), and high-dose (≥20 mg prednisone daily).
• Abdominal tenderness was the only consistent clinical sign in the high-dose GCS group.
• Patients on high-dose GCS experienced a significantly longer delay (8.3 days) from symptom onset to treatment compared to low-dose or perioperative groups (1.7-2.2 days).

Findings:

• Mortality rates increased dramatically with GCS dosage: 11.8% (group 1), 13.3% (group 2), and 85% (group 3).
• High-dose GCS therapy attenuated the clinical signs of peritonitis, hindering early recognition of gastrointestinal perforation.
• Delayed diagnosis and treatment in the high-dose GCS group directly correlated with increased mortality.

Implications:

• Clinical suspicion for gastrointestinal perforation must be heightened in patients receiving high-dose GCS, even with subtle abdominal discomfort.
• Aggressive diagnostic evaluation is warranted for persistent abdominal pain in this patient population.
• Prompt surgical exploration should be considered for suspected gastrointestinal perforation in patients on high-dose GCS to improve outcomes.